Takuya Tsujino

Junior Associate Professor

Osaka Medical and Pharmaceutical University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Takuya Tsujino is a Junior Associate Professor at Osaka Medical and Pharmaceutical University in Japan. His research areas include the mechanisms of drug sensitivity in prostate cancer, the efficacy of treatments for metastatic urothelial carcinoma, and immune-related adverse events in cancer therapy. Recent publications focus on improving treatment responses through targeted therapies and understanding genetic determinants of cancer progression.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Marian Kalocsay

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Taizo Uchimoto

JAPAN

View details

Seiji Arai

Gunma University

JAPAN

View details

Li Jia

Assistant Professor

Brigham and Women's Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Takuya Tsujino

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Acute BRCAness Induction and AR Pathway Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer

Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan

Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors

Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study

Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on NLR Fluctuation and Liver Metastases.

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract

Genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma

Collaborators (4)

Marian Kalocsay

Taizo Uchimoto

Seiji Arai

Li Jia

Make your next move.